Comparative Pharmacology
Head-to-head clinical analysis: HAILEY 1 5 30 versus KAITLIB FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY 1 5 30 versus KAITLIB FE.
HAILEY 1.5/30 vs KAITLIB FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is 13-27 hours (mean 17 hours); for norgestimate, active metabolite norelgestromin has half-life 12-30 hours (mean 19 hours). Steady state reached after 7-14 days.
Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing
Approximately 40% renal (as metabolites), 32% fecal (as metabolites), and <1% unchanged in urine.
Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20%
Category C
Category C
Oral Contraceptive
Oral Contraceptive